Not a good buy right now for an impatient investor: the tape is still weak (bearish/expanding negative MACD) and the stock is trading below near-term support levels.
Short-term bounce risk is real (RSI ~26.8 = oversold), but the current setup looks more like a falling-knife oversold than a confirmed reversal.
Options positioning is somewhat supportive (low OI put/call), but extremely high IV into an upcoming earnings event implies elevated uncertainty.
Trend/structure: Momentum is bearish; MACD histogram is -0.337 and negatively expanding, signaling the down-move is still strengthening.
RSI: RSI_6 = 26.759 (effectively oversold), which can precede a short rebound, but is not a reversal confirmation by itself.
Moving averages: Converging MAs suggest indecision/transition, but not yet a clear uptrend.
Key levels:
Current: 16.035
S1: 16.358 (price is below this level → former support acting as resistance)
S2: 15.505 (next downside level)
Pivot: 17.737 (would need to reclaim to improve the trend)
R1/R2: 19.117 / 19.969
Pattern-based odds (provided): ~80% chance of +2.21% next day / +2.26% next week, but -7.78% next month, aligning with weak intermediate momentum.
Options Data
Bullish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio
Positioning/sentiment:
Open interest put/call = 0.36 (more call OI than put OI → bullish leaning positioning)
Volume put/call = 1.0 (today’s flow is neutral)
Volatility:
IV (30d) 135.26 vs historical vol 54.75 → options are very expensive, consistent with elevated event risk/uncertainty.
IV percentile 77.29 (IV is high versus its own history).
Activity:
Today’s volume is low in absolute terms (4 contracts), so don’t over-weight today’s flow.
Volume vs 30D avg: 4.21x suggests a relative spike, but from a small base.
Practical read: market is pricing a big move (high IV), while OI skews bullish; direction is still unclear near-term.
Technical Summary
Sell
6
Buy
7
Positive Catalysts
can support a near-term relief bounce if selling pressure fades.
Neutral/Negative Catalysts
keeps near-term trend pressure on.
Financial Performance
Latest reported quarter: 2025/Q4
Revenue: $13.577M, +2.21% YoY (modest growth).
Net income: -$78.221M, improved 33.60% YoY (loss narrowed).
EPS: -$0.82, improved 9.33% YoY.
Gross margin: 100% (typical for collaboration/recognized revenue mix; not the key driver—cash burn and pipeline progress matter more).
Takeaway: financials show incremental improvement, but profitability is not near-term; the stock will trade primarily on clinical/regulatory execution and updates.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: predominantly bullish with multiple Buy/Overweight reiterations and several price target raises after updates.
Upgrades/raises (highlights):
Morgan Stanley upgraded to Overweight and raised PT to $36 (from $15) on improved probability of success and pipeline optionality.
Piper Sandler raised PT to $35; Stifel raised PT to $35; H.C. Wainwright raised PT to $32; Mizuho raised PT to $30; BTIG raised PT to $30; Truist initiated/assumed with Buy and PT $30.
Mixed note: Wells Fargo trimmed PT to $29 (from $30) but maintained Overweight; JPMorgan lowered PT to $22 (from $30) while keeping Overweight.
Wall Street pros: strong conviction around bexobrutideg differentiation/tolerability and platform optionality.
Wall Street cons: fewer near-term 2026 clinical catalysts and timing push toward 2H 2026/2027 for major value-inflection.
Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 28.93 USD with a low forecast of 12 USD and a high forecast of 41 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 28.93 USD with a low forecast of 12 USD and a high forecast of 41 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 15.950
Low
12
Averages
28.93
High
41
Current: 15.950
Low
12
Averages
28.93
High
41
Piper Sandler
Overweight
maintain
$32 -> $35
AI Analysis
2026-01-29
Reason
Piper Sandler
Price Target
$32 -> $35
AI Analysis
2026-01-29
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Nurix Therapeutics to $35 from $32 and keeps an Overweight rating on the shares following quarterly results and pipeline update. The firm notes that after the recent Phase 1 update in chronic lymphocytic leukemia/small lymphocytic lymphoma at ASH 2025, bexobrutideg pivotal development is accelerating, as the confirmatory Phase 3 trial in second-line and later CLL/SLL for potential full approval is initiating in the first half of 2026 and the first patients were dosed in the single-arm Phase 2 in the third-line and later setting in Q4 2025 for potential accelerated approval. Piper now anticipates a bexobrutideg update in relapsed/refractory non-Hodgkin lymphoma in 2026.
Wells Fargo
Derek Archila
Overweight
downgrade
$30 -> $29
2026-01-29
Reason
Wells Fargo
Derek Archila
Price Target
$30 -> $29
2026-01-29
downgrade
Overweight
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Nurix Therapeutics to $29 from $30 and keeps an Overweight rating on the shares. While there are not a ton of clinical catalysts in 2026, the firm thinks shares remain undervalued. Wells believes the setup will improve in the second half of 2026 ahead of several key catalysts in 2027 that could have the stock materially higher.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRIX
